Drug intelligence / Profile preview

grass pollen allergenic extract (Lolium perenne) + grass pollen allergenic extract (Cynodon dactylon)

Development stage
Unknown
Lead developer
Leti Pharma
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

This drug is a combination of standardized allergenic extracts from two types of grass pollen: Perennial Ryegrass (Lolium perenne) and Bermuda Grass (Cynodon dactylon). It is used for allergen-specific immunotherapy in patients with allergic rhinitis (hay fever), with or without conjunctivitis, caused by these specific pollens. The treatment works by modulating the immune system's response to these allergens. By administering gradually increasing doses of the extracts, the therapy aims to induce immunological tolerance, which reduces the severity of allergy symptoms upon environmental exposure. The underlying mechanism is believed to involve a shift from a T-helper 2 (Th2) cell-dominated, pro-allergic response to a T-helper 1 (Th1) and regulatory T-cell (Treg) dominated, tolerant state. This leads to a decrease in allergen-specific IgE antibodies and an increase in blocking antibodies like IgG4. This combination is typically prepared by a healthcare professional as a custom formulation for subcutaneous injection, based on the patient's specific sensitivities confirmed by diagnostic testing. [8, 13, 15]

Other names
Perennial Ryegrass and Bermuda Grass allergenic extract
02

Targets

High-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E complex

Beyond the preview

Go deeper on grass pollen allergenic extract (Lolium perenne) + grass pollen allergenic extract (Cynodon dactylon).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on grass pollen allergenic extract (Lolium perenne) + grass pollen allergenic extract (Cynodon dactylon).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call